{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T12:34:45Z","timestamp":1786970085738,"version":"build-2736575974"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T00:00:00Z","timestamp":1763769600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T00:00:00Z","timestamp":1763769600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Open Research Project of the National Clinical Research Center for Traditional Chinese Medicine Acupuncture","award":["NCRCOP2024009"],"award-info":[{"award-number":["NCRCOP2024009"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"DOI":"10.1007\/s00277-025-06720-4","type":"journal-article","created":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T02:11:46Z","timestamp":1763777506000},"page":"6205-6214","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["MiR-503-5p as a potential biomarker for deep venous thrombosis (DVT) in multiple myeloma (MM) and its role in disease development"],"prefix":"10.1007","volume":"104","author":[{"given":"Yifei","family":"Guo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lixiang","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenyang","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reaila","family":"Jianati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanan","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaogang","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Ju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhexin","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,22]]},"reference":[{"issue":"6","key":"6720_CR1","doi-asserted-by":"publisher","first-page":"2962","DOI":"10.1182\/blood-2007-10-078022","volume":"111","author":"RA Kyle","year":"2008","unstructured":"Kyle RA, Rajkumar SV (2008) Multiple myeloma. Blood 111(6):2962\u20132972","journal-title":"Blood"},{"issue":"1Suppl 1","key":"6720_CR2","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1002\/hon.2586","volume":"37","author":"SV Rajkumar","year":"2019","unstructured":"Rajkumar SV (2019) Multiple myeloma: every year a new standard? Hematol Oncol 37(1Suppl 1):62\u201365","journal-title":"Hematol Oncol"},{"key":"6720_CR3","doi-asserted-by":"crossref","unstructured":"Rodriguez-Otero P, Paiva B, San-Miguel JF (2021) Roadmap to cure multiple myeloma. Cancer Treat Rev. ; 100102284","DOI":"10.1016\/j.ctrv.2021.102284"},{"issue":"1","key":"6720_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-31430-0","volume":"13","author":"JN Vo","year":"2022","unstructured":"Vo JN, Wu YM, Mishler J, Hall S, Mannan R, Wang L et al (2022) The genetic heterogeneity and drug resistance mechanisms of relapsed refractory multiple myeloma. Nat Commun 13(1):3750","journal-title":"Nat Commun"},{"issue":"12","key":"6720_CR5","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1080\/10428194.2023.2247513","volume":"64","author":"O Jarchowsky","year":"2023","unstructured":"Jarchowsky O, Avnery O, Ellis MH (2023) Thrombosis in multiple myeloma: mechanisms, risk assessment and management. Leuk Lymphoma 64(12):1905\u20131913","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"6720_CR6","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1002\/ajh.26806","volume":"98","author":"C Charalampous","year":"2023","unstructured":"Charalampous C, Goel U, Kapoor P, Binder M, Buadi FK, Dingli D et al (2023) Thrombosis in multiple myeloma: risk estimation by induction regimen and association with overall survival. Am J Hematol 98(3):413\u2013420","journal-title":"Am J Hematol"},{"issue":"11","key":"6720_CR7","doi-asserted-by":"publisher","first-page":"2536","DOI":"10.3324\/haematol.2022.280893","volume":"107","author":"V De Stefano","year":"2022","unstructured":"De Stefano V, Larocca A, Carpenedo M, Cavo M, Di Raimondo F, Falanga A et al (2022) Thrombosis in multiple myeloma: risk stratification, antithrombotic prophylaxis, and management of acute events. A consensus-based position paper from an ad hoc expert panel. Haematologica 107(11):2536\u20132547","journal-title":"Haematologica"},{"issue":"3","key":"6720_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.rpth.2025.102865","volume":"9","author":"C Codreanu","year":"2025","unstructured":"Codreanu C, Elling T, Veeger N, Roeloffzen WWH, Meijer K (2025) A systematic review of direct oral anticoagulants for thromboprophylaxis in multiple myeloma. Res Pract Thromb Haemost 9(3):102865","journal-title":"Res Pract Thromb Haemost"},{"issue":"7","key":"6720_CR9","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1002\/rth2.12411","volume":"4","author":"MW Schoen","year":"2020","unstructured":"Schoen MW, Carson KR, Luo S, Gage BF, Li A, Afzal A et al (2020) Venous thromboembolism in multiple myeloma is associated with increased mortality. Res Pract Thromb Haemost 4(7):1203\u20131210","journal-title":"Res Pract Thromb Haemost"},{"key":"6720_CR10","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S533589","author":"Y Guo","year":"2025","unstructured":"Guo Y, Yan L, Yang X, Fan C, Reaila J, Jia Y et al (2025) Study on risk factors and treatment strategies for deep vein thrombosis in patients with multiple myeloma. Cancer Manag Res. https:\/\/doi.org\/10.2147\/CMAR.S533589","journal-title":"Cancer Manag Res"},{"key":"6720_CR11","doi-asserted-by":"crossref","unstructured":"O\u2019Brien J, Hayder H, Zayed Y, Peng C (2018) Overview of MicroRNA Biogenesis, mechanisms of Actions, and circulation. Front Endocrinol (Lausanne). ; 9402","DOI":"10.3389\/fendo.2018.00402"},{"issue":"3","key":"6720_CR12","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/s41576-023-00662-1","volume":"25","author":"K Nemeth","year":"2024","unstructured":"Nemeth K, Bayraktar R, Ferracin M, Calin GA (2024) Non-coding RNAs in disease: from mechanisms to therapeutics. Nat Rev Genet 25(3):211\u2013232","journal-title":"Nat Rev Genet"},{"issue":"1","key":"6720_CR13","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1002\/ijc.31041","volume":"142","author":"B Tang","year":"2018","unstructured":"Tang B, Xu A, Xu J, Huang H, Chen L, Su Y et al (2018) Microrna-324-5p regulates stemness, pathogenesis and sensitivity to bortezomib in multiple myeloma cells by targeting Hedgehog signaling. Int J Cancer 142(1):109\u2013120","journal-title":"Int J Cancer"},{"issue":"6","key":"6720_CR14","doi-asserted-by":"publisher","first-page":"3492","DOI":"10.1111\/jcmm.15035","volume":"24","author":"X Shen","year":"2020","unstructured":"Shen X, Kong S, Yang Q, Yin Q, Cong H, Wang X et al (2020) PCAT-1 promotes cell growth by sponging miR-129 via MAP3K7\/NF-\u03baB pathway in multiple myeloma. J Cell Mol Med 24(6):3492\u20133503","journal-title":"J Cell Mol Med"},{"issue":"10","key":"6720_CR15","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.2174\/13894501113149990186","volume":"14","author":"M Rossi","year":"2013","unstructured":"Rossi M, Amodio N, Di Martino MT, Caracciolo D, Tagliaferri P, Tassone P (2013) From target therapy to MiRNA therapeutics of human multiple myeloma: theoretical and technological issues in the evolving scenario. Curr Drug Targets 14(10):1144\u20131149","journal-title":"Curr Drug Targets"},{"key":"6720_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232314765","author":"M Vlachov\u00e1","year":"2022","unstructured":"Vlachov\u00e1 M, Gregorov\u00e1 J, Vychytilov\u00e1-Faltejskov\u00e1 P, Gab\u0142o NA, Radov\u00e1 L, Posp\u00ed\u0161ilov\u00e1 L et al (2022) Involvement of small non-coding RNA and cell antigens in pathogenesis of extramedullary multiple myeloma. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms232314765","journal-title":"Int J Mol Sci"},{"issue":"1","key":"6720_CR17","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/s41416-021-01602-8","volume":"126","author":"MA Papadimitriou","year":"2022","unstructured":"Papadimitriou MA, Papanota AM, Adamopoulos PG, Pilala KM, Liacos CI, Malandrakis P et al (2022) MiRNA-seq and clinical evaluation in multiple myeloma: miR-181a overexpression predicts short-term disease progression and poor post-treatment outcome. Br J Cancer 126(1):79\u201390","journal-title":"Br J Cancer"},{"key":"6720_CR18","doi-asserted-by":"crossref","unstructured":"Liu S, Wang L, Wu X, Wu J, Liu D, Yu H (2022) Overexpression of hsa_circ_0022742 suppressed hyperglycemia-induced endothelial dysfunction by targeting the miR-503-5p\/FBXW7 axis. Microvasc Res. ; 139104249","DOI":"10.1016\/j.mvr.2021.104249"},{"issue":"2","key":"6720_CR19","doi-asserted-by":"publisher","DOI":"10.3390\/cells14020144","volume":"14","author":"MP Donadini","year":"2025","unstructured":"Donadini MP, Calcaterra F, Romualdi E, Ciceri R, Cancellara A, Lodigiani C et al (2025) The link between venous and arterial thrombosis: is there a role for endothelial dysfunction? Cells 14(2):144","journal-title":"Cells"},{"key":"6720_CR20","doi-asserted-by":"crossref","unstructured":"Vishnoi A, Rani S (2023) MiRNA biogenesis and regulation of diseases: an updated overview. Methods Mol Biol. ; 25951\u201325912","DOI":"10.1007\/978-1-0716-2823-2_1"},{"issue":"5","key":"6720_CR21","doi-asserted-by":"publisher","first-page":"5609","DOI":"10.1007\/s11033-019-04895-4","volume":"46","author":"M Pashirzad","year":"2019","unstructured":"Pashirzad M, Fiuji H, Khazei M, Moradi-Binabaj M, Ryzhikov M, Shabani M et al (2019) Role of Wnt3a in the pathogenesis of cancer, current status and prospective. Mol Biol Rep 46(5):5609\u20135616","journal-title":"Mol Biol Rep"},{"issue":"12","key":"6720_CR22","first-page":"554","volume":"34","author":"S He","year":"2015","unstructured":"He S, Lu Y, Liu X, Huang X, Keller ET, Qian CN et al (2015) Wnt3a: functions and implications in cancer. Chin J Cancer 34(12):554\u2013562","journal-title":"Chin J Cancer"},{"key":"6720_CR23","doi-asserted-by":"crossref","unstructured":"Qiang YW, Shaughnessy JD Jr, Yaccoby S (2008) Wnt3a signaling within bone inhibits multiple myeloma bone disease and tumor growth. Blood 112(2):374\u2013382","DOI":"10.1182\/blood-2007-10-120253"},{"issue":"9","key":"6720_CR24","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1016\/j.yexcr.2012.12.023","volume":"319","author":"M Reis","year":"2013","unstructured":"Reis M, Liebner S (2013) Wnt signaling in the vasculature. Exp Cell Res 319(9):1317\u20131323","journal-title":"Exp Cell Res"},{"issue":"2","key":"6720_CR25","doi-asserted-by":"publisher","first-page":"421","DOI":"10.3892\/mmr.2012.916","volume":"6","author":"A Kondo","year":"2012","unstructured":"Kondo A, Tokuda H, Mizutani J, Matsushima-Nishiwaki R, Kozawa O, Otsuka T (2012) Wnt3a upregulates prostaglandin F2\u03b1-stimulated vascular endothelial growth factor synthesis in osteoblasts. Mol Med Rep 6(2):421\u2013425","journal-title":"Mol Med Rep"},{"key":"6720_CR26","doi-asserted-by":"crossref","unstructured":"Sch\u00f6nichen C, Sun S, Middelveld H, Huskens D, de Groot PG, Heemskerk JWM et al (2024) Functionally distinct anticoagulant mechanisms of endothelial cells. Thromb Res. ; 244109208","DOI":"10.1016\/j.thromres.2024.109208"},{"key":"6720_CR27","doi-asserted-by":"crossref","unstructured":"Gao L, Li L, Hu J, Li G, Zhang Y, Dai X et al (2022) Metformin inhibits multiple myeloma Serum-induced endothelial cell thrombosis by Down-Regulating miR-532. Ann Vasc Surg. ; 85347\u201357e2","DOI":"10.1016\/j.avsg.2022.04.035"},{"issue":"8","key":"6720_CR28","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1080\/10428194.2023.2216325","volume":"64","author":"P Zhou","year":"2023","unstructured":"Zhou P, Li W, Zuo S, Ma R, Yuan X, Zhu Z (2023) Pathogenesis, clinical characteristics and personalized managements of multiple myeloma with chromosome 1 abnormalities. Leuk Lymphoma 64(8):1373\u20131388","journal-title":"Leuk Lymphoma"},{"key":"6720_CR29","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21145002","author":"S Akhtar","year":"2020","unstructured":"Akhtar S, Ali TA, Faiyaz A, Khan OS, Raza SS, Kulinski M et al (2020) Cytokine-mediated dysregulation of signaling pathways in the pathogenesis of multiple myeloma. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms21145002","journal-title":"Int J Mol Sci"},{"issue":"3","key":"6720_CR30","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1586\/14737140.7.3.307","volume":"7","author":"M Zangari","year":"2007","unstructured":"Zangari M, Elice F, Fink L, Tricot G (2007) Thrombosis in multiple myeloma. Expert Rev Anticancer Ther 7(3):307\u2013315","journal-title":"Expert Rev Anticancer Ther"},{"key":"6720_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2017.09.013","volume":"62","author":"O Gutwein","year":"2017","unstructured":"Gutwein O, Rahimi-Levene N, Herzog-Tzarfati K, Garach-Jehoshua O, Nagler A, Izak M et al (2017) Low protein Z levels in patients with plasma cell neoplasms are inversely correlated with IL-6 levels. Leuk Res 62:104\u201362107","journal-title":"Leuk Res"},{"issue":"5","key":"6720_CR32","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2020.12126","volume":"20","author":"L Zhong","year":"2020","unstructured":"Zhong L, Jin X, Xu Z, Zeng M, Chen D, He Y et al (2020) Circulating miR-451a levels as a potential biomarker to predict the prognosis of patients with multiple myeloma. Oncol Lett 20(5):263","journal-title":"Oncol Lett"},{"key":"6720_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.reth.2019.12.002","author":"K Chen","year":"2020","unstructured":"Chen K, Zhao XL, Li LB, Huang LY, Tang Z, Luo J et al (2020) MiR-503\/Apelin-12 mediates high glucose-induced microvascular endothelial cells injury via JNK and p38MAPK signaling pathway. Regen Ther. https:\/\/doi.org\/10.1016\/j.reth.2019.12.002","journal-title":"Regen Ther"},{"issue":"3","key":"6720_CR34","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/s00441-021-03471-2","volume":"387","author":"K Neubauer","year":"2022","unstructured":"Neubauer K, Zieger B (2022) Endothelial cells and coagulation. Cell Tissue Res 387(3):391\u2013398","journal-title":"Cell Tissue Res"},{"key":"6720_CR35","doi-asserted-by":"crossref","unstructured":"Wen Y, Chen R, Zhu C, Qiao H, Liu Y, Ji H et al (2018) MiR-503 suppresses hypoxia-induced proliferation, migration and angiogenesis of endothelial progenitor cells by targeting Apelin. Peptides. ; 10558\u201310565","DOI":"10.1016\/j.peptides.2018.05.008"},{"issue":"7","key":"6720_CR36","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1182\/blood-2014-05-578781","volume":"127","author":"F Adam","year":"2016","unstructured":"Adam F, Khatib AM, Lopez JJ, Vatier C, Turpin S, Muscat A et al (2016) Apelin: an antithrombotic factor that inhibits platelet function. Blood 127(7):908\u2013920","journal-title":"Blood"},{"issue":"3","key":"6720_CR37","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1055\/s-2003-40965","volume":"29","author":"M Zangari","year":"2003","unstructured":"Zangari M, Saghafifar F, Mehta P, Barlogie B, Fink L, Tricot G (2003) The blood coagulation mechanism in multiple myeloma. Semin Thromb Hemost 29(3):275\u2013282","journal-title":"Semin Thromb Hemost"},{"key":"6720_CR38","doi-asserted-by":"crossref","unstructured":"Branchford BR, Carpenter SL (2018) The role of inflammation in venous thromboembolism. Front Pediatr. ; 6142","DOI":"10.3389\/fped.2018.00142"},{"issue":"1","key":"6720_CR39","doi-asserted-by":"publisher","first-page":"289","DOI":"10.2741\/e376","volume":"4","author":"B Osterud","year":"2012","unstructured":"Osterud B, Bjorklid E (2012) Tissue factor in blood cells and endothelial cells. Front Biosci (Elite Ed) 4(1):289\u2013299","journal-title":"Front Biosci (Elite Ed)"},{"issue":"6","key":"6720_CR40","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1097\/MBC.0b013e328348629d","volume":"22","author":"A Hoshi","year":"2011","unstructured":"Hoshi A, Matsumoto A, Chung J, Isozumi Y, Koyama T (2011) Activation of coagulation by a thalidomide-based regimen. Blood Coagul Fibrinolysis 22(6):532\u2013540","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"10","key":"6720_CR41","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1096\/fasebj.9.10.7615164","volume":"9","author":"CT Esmon","year":"1995","unstructured":"Esmon CT (1995) Thrombomodulin as a model of molecular mechanisms that modulate protease specificity and function at the vessel surface. FASEB J 9(10):946\u2013955","journal-title":"FASEB J"},{"issue":"5","key":"6720_CR42","first-page":"876","volume":"112","author":"AR Rezaie","year":"2014","unstructured":"Rezaie AR (2014) Protease-activated receptor signalling by coagulation proteases in endothelial cells. Thromb Haemost 112(5):876\u2013882","journal-title":"Thromb Haemost"},{"key":"6720_CR43","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2022248118","author":"H Giri","year":"2021","unstructured":"Giri H, Panicker SR, Cai X, Biswas I, Weiler H, Rezaie AR (2021) Thrombomodulin is essential for maintaining quiescence in vascular endothelial cells. Proc Natl Acad Sci U S A. https:\/\/doi.org\/10.1073\/pnas.2022248118","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"6720_CR44","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1093\/neuonc\/noae176","volume":"27","author":"KH Ho","year":"2025","unstructured":"Ho KH, Trapp M, Guida C, Ivanova EL, De Jaime-Soguero A, Jabali A et al (2025) Activation of Wnt\/\u03b2-catenin signaling is critical for the tumorigenesis of choroid plexus. Neuro Oncol 27(1):106\u2013122","journal-title":"Neuro Oncol"},{"issue":"4","key":"6720_CR45","first-page":"3138","volume":"20","author":"B Du","year":"2020","unstructured":"Du B, Wang J, Zang S, Mao X, Du Y (2020) Long non-coding RNA MALAT1 suppresses the proliferation and migration of endothelial progenitor cells in deep vein thrombosis by regulating the Wnt\/\u03b2-catenin pathway. Exp Ther Med 20(4):3138\u20133146","journal-title":"Exp Ther Med"},{"issue":"1","key":"6720_CR46","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-62582-2","volume":"14","author":"F Yang","year":"2024","unstructured":"Yang F, Guo J, Kang N, Yu X, Ma Y (2024) rESWT promoted angiogenesis via Bach1\/Wnt\/\u03b2-catenin signaling pathway. Sci Rep 14(1):11733","journal-title":"Sci Rep"},{"issue":"4","key":"6720_CR47","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1161\/CIRCRESAHA.115.306829","volume":"117","author":"L Jiang","year":"2015","unstructured":"Jiang L, Yin M, Wei X, Liu J, Wang X, Niu C et al (2015) Bach1 represses Wnt\/\u03b2-catenin signaling and angiogenesis. Circ Res 117(4):364\u2013375","journal-title":"Circ Res"},{"issue":"12","key":"6720_CR48","doi-asserted-by":"publisher","DOI":"10.1002\/jbt.23213","volume":"36","author":"L Huang","year":"2022","unstructured":"Huang L, Liu M, Jiang W, Ding H, Han Y, Wen M et al (2022) Bradykinin\/bradykinin 1 receptor promotes brain microvascular endothelial cell permeability and proinflammatory cytokine release by downregulating Wnt3a. J Biochem Mol Toxicol 36(12):e23213","journal-title":"J Biochem Mol Toxicol"},{"key":"6720_CR49","doi-asserted-by":"crossref","unstructured":"Zhang J, Chen S, Xiang H, Xiao J, Zhao S, Shu Z et al (2023) S1PR2\/Wnt3a\/RhoA\/ROCK1\/beta-catenin signaling pathway promotes diabetic nephropathy by inducting endothelial mesenchymal transition and impairing endothelial barrier function. Life Sci. ; 328121853","DOI":"10.1016\/j.lfs.2023.121853"},{"key":"6720_CR50","doi-asserted-by":"crossref","unstructured":"Song J, Jiang N, Gan X, Zhi W, Zhu Z (2021) Thrombin inhibitor Argatroban modulates bone marrow stromal cells behaviors and promotes osteogenesis through canonical Wnt signaling. Life Sci. ; 269119073","DOI":"10.1016\/j.lfs.2021.119073"},{"issue":"2","key":"6720_CR51","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.4049\/jimmunol.1000181","volume":"185","author":"J Kim","year":"2010","unstructured":"Kim J, Kim J, Kim DW, Ha Y, Ihm MH, Kim H et al (2010) Wnt5a induces endothelial inflammation via beta-catenin-independent signaling. J Immunol 185(2):1274\u20131282","journal-title":"J Immunol"},{"issue":"1","key":"6720_CR52","doi-asserted-by":"publisher","DOI":"10.1186\/s11658-022-00328-6","volume":"27","author":"F Wang","year":"2022","unstructured":"Wang F, Hou W, Li X, Lu L, Huang T, Zhu M et al (2022) SETD8 cooperates with MZF1 to participate in hyperglycemia-induced endothelial inflammation via elevation of WNT5A levels in diabetic nephropathy. Cell Mol Biol Lett 27(1):30","journal-title":"Cell Mol Biol Lett"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06720-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-025-06720-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06720-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,4]],"date-time":"2026-01-04T00:15:02Z","timestamp":1767485702000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-025-06720-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,22]]},"references-count":52,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["6720"],"URL":"https:\/\/doi.org\/10.1007\/s00277-025-06720-4","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,22]]},"assertion":[{"value":"30 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of First Teaching Hospital of Tianjin University of Traditional Chinese Medicine.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}},{"value":"The authors declare no competing interests.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}